Outlook Therapeutics Faces Investor Backlash Post-FDA Approval: A Cautionary Tale
Outlook Therapeutics (OTLK) faces investor backlash as capital raise impacts share prices despite FDA approval of LYTENAVA.
Cullinan Oncology's Path to FDA Approval: What Investors Need to Know
Cullinan Oncology's recent Phase 3 trial results signal a pivotal moment for investors as the company pursues FDA approval.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Rocket Lab's Strategic Move: Clearing Regulatory Hurdles in the Iridium Acquisition
Rocket Lab's acquisition of Iridium marks a pivotal shift towards integrated space infrastructure, impacting the broader…
Cullinan Oncology's Stock Surge: Analyzing the Impact of Phase 3 Trial Results
Cullinan Oncology's positive Phase 3 trial results could reshape its market position and attract significant investor in…
Neurocrine Biosciences (NBIX) Faces Regulatory Scrutiny After Safety Concerns: What Investors Should Know
Neurocrine Biosciences (NBIX) faces scrutiny from regulators following safety alarms, including seven patient deaths. He…
Definium Therapeutics (DFTX) Phase 3 Trial Success: A Potential Game Changer for Anxiety Treatment
Definium Therapeutics' successful Phase 3 trial results could reshape anxiety treatment and boost investor sentiment.
Clean Harbors Expands Footprint with $470 Million EnviroServe Acquisition
Clean Harbors is set to bolster its environmental services capabilities with the $470 million acquisition of EnviroServe…
Definium Therapeutics Soars on Trial Success: What This Means for Investors
Definium Therapeutics stock surged 20% following positive Phase 3 trial results, signaling a significant de-risking even…
Regulatory Concerns Hit Neurocrine Biosciences: A Closer Look at NBIX's Safety Woes
Neurocrine Biosciences faces scrutiny after seven patient deaths linked to its drug raise regulatory alarm bells.
Nasdaq's Strategic Acquisition of LeveL Markets: Implications for 24/7 Trading
Nasdaq's acquisition of LeveL Markets signals a major shift towards extended trading hours, reshaping market infrastruct…
AbCellera's ABCL635: Positive Data Fuels Market Optimism and Analyst Upgrades
AbCellera Biologics' positive Phase 2 results for ABCL635 have led to increased analyst confidence and price target adju…